Vivus resubmits application for Qnexa

MOUNTAIN VIEW, Calif. — Vivus has reapplied to the Food and Drug Administration for approval of a drug to treat obesity, the company said Monday.



Vivus said it sent in its regulatory approval application for Qnexa (phentermine and topiramate), a drug designed to treat obese and overweight patients by inducing and maintaining weight loss.



The company originally sought approval for the drug in October 2010, though the FDA declined to approve it.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.